Retatrutide
Reta · Triple-G · LY3437943
An investigational triple receptor agonist (GIP, GLP-1 and glucagon) conjugated to a fatty-diacid for albumin binding, studied in trials for obesity and metabolic disease. Its half-life supports once-weekly administration.
Half-life
~6 days, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.
References
- Jastreboff et al., NEJM 2023 (phase 2 obesity)
- Nature Medicine 2024 (phase 2a MASLD)
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.